{"id":"W4322617370","doi":"10.1128/aac.01514-22","title":"Safety, Tolerability, and Pharmacokinetics of Anti-SARS-CoV-2 Immunoglobulin Intravenous (Human) Investigational Product (COVID-HIGIV) in Healthy Adults: a Randomized, Controlled, Double-Blinded, Phase 1 Study","year":2023,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"SARS-CoV-2 and COVID-19 Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Emergent BioSolutions (Canada)","funders":"Defense Health Agency; U.S. Department of Defense","keywords":"Pharmacokinetics; Coronavirus disease 2019 (COVID-19); Medicine; Tolerability; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 2019-20 coronavirus outbreak; Pharmacology; Adverse effect; Virology; Internal medicine; Infectious disease (medical specialty)","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002901099,0.001708128,0.001785125,0.0004706212,0.0005313696,0.0006673241,0.0005876909,0.001557569,0.003331713],"category_scores_gemma":[0.002197067,0.0008117337,0.001224861,0.0004374897,0.001449635,0.00108746,0.0003056454,0.002541127,0.0006161779],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000593252,"about_ca_system_score_gemma":0.00123754,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004744349,"about_ca_topic_score_gemma":0.0009815777,"domain_scores_codex":[0.9987685,0.000759352,0.00007452829,0.0001621793,0.0001153682,0.0001200172],"domain_scores_gemma":[0.9983786,0.0004717567,0.0003957417,0.0001189119,0.0001338147,0.0005012415],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8851933,0.05686919,0.003895365,0.0004318936,0.0007314777,0.0001001788,0.0001623547,0.0006386442,0.01310623,0.00009078466,0.0009515898,0.037829],"study_design_scores_gemma":[0.3763632,0.6100389,0.00921955,0.00002098044,0.0004396344,0.00009826329,0.00004293575,0.0005937142,0.002342324,0.00009466964,0.0007212438,0.00002461524],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.993553,0.00152211,0.0007677102,0.0001307449,0.00009852758,0.002759509,0.0004806893,0.00005181997,0.0006358683],"genre_scores_gemma":[0.9913926,0.001465811,0.001754704,0.0005411642,0.0003388031,0.002317725,0.0007073361,0.00002742573,0.001454512],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003331713,"threshold_uncertainty_score":0.01534265,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06098311271928428,"score_gpt":0.3942140983941348,"score_spread":0.3332309856748505,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}